The market for initial public offerings is clearly heating up.
Beyond the buzz of unicorns preparing to go public, two biopharmaceutical companies backed by hedge funds have disclosed their IPO plans with little fanfare. Ideaya Biosciences and Bicycle Therapeutics each filed on April 26 preliminary documents for a public offering.
Neither
